CASTRO-B - Study on CRP Apheresis in STROke Patients in Berlin — CASTRO-B  

Stroke, Ischemic Clinical Trial

Official title: Selective Depletion of C-reactive Protein (CRP) With Therapeutic Apheresis (CRP Apheresis) in Stroke

Status Recruiting

Clinical Trial Summary

This study explores the use of CRP level reduction in patients after suffering from acute ischemic stroke. Using selective CRP-apheresis, the investigators aim to reduce the secondary inflammatory tissue damage in the course of infarction maturation using infarction growth in MRI as the primary outcome as a surrogate.

Clinical Trial Description

C-reactive protein (CRP) is an acute-phase protein binding to phosphocholine, thereby marking damaged tissue. This in turn activates the complement system and the cellular immune system engaging the unspecific immune system in an inflammatory tissue-degrading reaction. Such a pattern is observed in ischemic stroke, and elevated CRP levels can be measured in stroke survivors' sera. Several observational studies reproduced higher CRP levels with negative outcome in stroke. In another vascular model disease, myocardial infarction, selective CRP apheresis reduced infarct size in humans. The investigators therefore designed this pilot study to explore the effects of selective CRP reduction in ischemic stroke patients. ;

Related Conditions & MeSH terms

• Ischemic Stroke
• Stroke
• Stroke, Ischemic

• NCT number: NCT03884153
• Study type: Interventional
• Source: Charite University, Berlin, Germany
• Contact: Benjamin Hotter, Dr. med.
• Phone: +49 30 450 639729
• Email: benjamin.hotter@charite.de
• Status: Recruiting
• Phase: N/A
• Start date: December 3, 2020
• Completion date: December 31, 2022